MedPath

Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarcoma

Phase 1
Recruiting
Conditions
Metastatic soft tissue sarcoma
Therapeutic area: Diseases [C] - Neoplasms [C04]
Registration Number
CTIS2024-515551-38-00
Lead Sponsor
Oncopole Claudius Regaud
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath